Premium
The effect of two doses of vitamin D3 (400 IU vs. 2000 IU/d) on serum 25‐hydroxyvitamin D in children with Crohn's disease
Author(s) -
Wingate Kirstin Emma,
Jacobson Kevan,
Issenman Robert,
Brill Herbert,
Barker Collin,
Israel David,
Carroll Matthew,
Weiler Hope,
Lamers Yvonne,
Barr Susan I.,
Green Tim J.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.347.2
Subject(s) - vitamin d and neurology , medicine , crohn's disease , alkaline phosphatase , vitamin d deficiency , gastroenterology , vitamin , endocrinology , calcifediol , disease , chemistry , biochemistry , enzyme
Vitamin D is crucial for Crohn's disease (CD) patients to maximize bone mineral density and because vitamin D insufficiency has been linked to increased disease activity. We tested whether 2000 IU/d ( vs . 400 IU/d) of vitamin D 3 yields a higher proportion of children with CD with serum 25‐hydroxyvitamin D (25OHD) concentration ≥ 50 or ≥ 75 nmol/L. 83 patients (8–18 yr) with quiescent CD (Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 10) were randomized to either 400 or 2000 IU/d for 6 months. Clinical and biochemical data were collected at baseline, 3 months and 6 months. Using an intention to treat analysis, at 6 months subjects receiving 2000 IU ( vs . 400 IU) were more likely to achieve 25OHD ≥ 75 nmol/L (75% vs. 34%; χ 2 =13, P<0.001), but proportions ≥ 50 nmol/L did not differ (94% vs. 91%). After adjustment for baseline 25OHD, mean (95% CI) serum 25OHD was higher in the 2000 IU group than the 400 IU group, 90 (84–96) vs. 67 (60–73) nmol/L (p<0.001), respectively. Disease activity assessed by the PCDAI, and serum bone specific alkaline phosphatase concentrations, were similar between groups. Vitamin D supplementation of 2000 IU/d allows most children with quiescent CD to reach serum 25OHD concentrations of ≥ 75 nmol/L, while 400 IU/d is associated with concentrations ≥ 50 nmol/L. Funding: University of British Columbia Vitamin Research Fund